CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
42.80
0.3%
Market Trading Hours* (UTC) Opens on Monday at 13:30

Mon - Thu: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.12
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

GSK plc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 42.94
Open* 42.99
1-Year Change* 22.83%
Day's Range* 42.81 - 43.16
52 wk Range 33.20-40.34
Average Volume (10 days) 2.91M
Average Volume (3 months) 64.81M
Market Cap 81.12B
P/E Ratio 10.48
Shares Outstanding 4.10B
Revenue 37.67B
EPS 3.77
Dividend (Yield %) 3.54758
Beta 0.65
Next Earnings Date Jan 31, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 28, 2024 42.81 -0.12 -0.28% 42.93 43.16 42.81
Mar 27, 2024 42.94 0.40 0.94% 42.54 42.97 42.45
Mar 26, 2024 42.74 -0.05 -0.12% 42.79 42.83 42.49
Mar 25, 2024 42.78 0.27 0.64% 42.51 43.38 42.50
Mar 22, 2024 42.30 -0.18 -0.42% 42.48 42.64 42.28
Mar 21, 2024 42.31 0.17 0.40% 42.14 42.49 42.08
Mar 20, 2024 41.88 -0.07 -0.17% 41.95 41.95 41.70
Mar 19, 2024 42.27 0.12 0.28% 42.15 42.27 42.02
Mar 18, 2024 42.09 -0.09 -0.21% 42.18 42.29 42.09
Mar 15, 2024 42.13 -0.06 -0.14% 42.19 42.38 41.75
Mar 14, 2024 43.03 -0.10 -0.23% 43.13 43.19 42.75
Mar 13, 2024 43.30 0.11 0.25% 43.19 43.31 43.02
Mar 12, 2024 43.20 0.32 0.75% 42.88 43.20 42.75
Mar 11, 2024 42.86 0.03 0.07% 42.83 42.90 42.67
Mar 8, 2024 43.08 0.15 0.35% 42.93 43.16 42.85
Mar 7, 2024 43.53 -0.15 -0.34% 43.68 43.78 43.43
Mar 6, 2024 42.57 0.21 0.50% 42.36 42.65 42.26
Mar 5, 2024 42.54 -0.01 -0.02% 42.55 42.72 42.43
Mar 4, 2024 42.37 0.37 0.88% 42.00 42.38 41.97
Mar 1, 2024 41.98 0.04 0.10% 41.94 42.02 41.72

GlaxoSmithKline plc Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 29324 24696 24354 33754 30821
Revenue 29324 24696 24354 33754 30821
Cost of Revenue, Total 8467 8006 7321 10168 9572
Gross Profit 20857 16690 17033 23586 21249
Total Operating Expense 22891 20375 18375 26793 25335
Selling/General/Admin. Expenses, Total 8128 6749 7025 10671 9408
Research & Development 5062 4525 4322 4338 3726
Depreciation / Amortization 91 101 75 64 44
Interest Expense (Income) - Net Operating 1433 1073 1220 -128 1839
Unusual Expense (Income) 529 355 -1205 2051 1038
Other Operating Expenses, Total -819 -434 -383 -371 -292
Operating Income 6433 4321 5979 6961 5486
Interest Income (Expense), Net Non-Operating -6 -1283 -400 -708 -602
Other, Net -799 561 -409 -32 -84
Net Income Before Taxes 5628 3599 5170 6221 4800
Net Income After Taxes 4921 3516 5103 5268 3921
Minority Interest -665 -711 -639 -623 -423
Net Income Before Extra. Items 4256 2805 4464 4645 3498
Net Income 14956 4385 5749 4645 3623
Income Available to Common Excl. Extra. Items 4256 2805 4464 4645 3498
Income Available to Common Incl. Extra. Items 14956 4385 5749 4645 3623
Dilution Adjustment
Diluted Net Income 14956 4385 5749 4645 3623
Diluted Weighted Average Shares 4084 4052 4030 4012.8 3976.8
Diluted EPS Excluding Extraordinary Items 1.04212 0.69225 1.10769 1.15755 0.8796
Dividends per Share - Common Stock Primary Issue 1 1
Diluted Normalized EPS 1.14153 0.6809 0.78859 1.69458 1.0682
Total Extraordinary Items 10700 1580 1285 125
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 7178 6951 7376 7829 6929
Revenue 7178 6951 7376 7829 6929
Cost of Revenue, Total 1892 1903 2177 2386 2136
Gross Profit 5286 5048 5199 5443 4793
Total Operating Expense 5037 4868 5508 6638 5848
Selling/General/Admin. Expenses, Total 2191 2065 2435 1968 1955
Research & Development 1315 1222 1522 1297 1155
Depreciation / Amortization 20 18 16 26 26
Unusual Expense (Income) -155 -160 -436 1216 735
Other Operating Expenses, Total -226 -180 -206 -255 -159
Operating Income 2141 2083 1868 1191 1081
Interest Income (Expense), Net Non-Operating -154 -176 -242 -179 -185
Net Income Before Taxes 1987 1907 1626 1012 896
Net Income After Taxes 1745 1631 1625 779 746
Minority Interest -121 -141 -125 -38 -137
Net Income Before Extra. Items 1624 1490 1500 741 609
Net Income 1624 1490 2001 10315 838
Income Available to Common Excl. Extra. Items 1624 1490 1500 741 609
Income Available to Common Incl. Extra. Items 1624 1490 2001 10315 838
Dilution Adjustment
Diluted Net Income 1624 1490 2001 10315 838
Diluted Weighted Average Shares 4093 4082.19 4087.34 4088.39 3220
Diluted EPS Excluding Extraordinary Items 0.39677 0.365 0.36699 0.18125 0.18913
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.37674 0.31919 0.25811 0.43734 0.37795
Total Extraordinary Items 0 501 9574 229
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 20769 18674 20247 19491 16927
Cash and Short Term Investments 7877 4335 6370 4786 3958
Cash 879 1427 1762 795 569
Short Term Investments 6998 2908 4608 3991 3389
Total Receivables, Net 7115 8031 7264 7148 6322
Accounts Receivable - Trade, Net 5471 6258 5562 5494 5185
Total Inventory 5146 5783 5996 5947 5476
Prepaid Expenses 343 315 359 316 330
Other Current Assets, Total 288 210 258 1294 841
Total Assets 60146 79103 80431 79692 58066
Property/Plant/Equipment, Total - Net 9620 10672 11006 11314 11058
Property/Plant/Equipment, Total - Gross 20138 21518 22313 22565 22488
Accumulated Depreciation, Total -10518 -10846 -11307 -11251 -11430
Goodwill, Net 7046 10552 10597 10562 5789
Intangibles, Net 14318 30079 29824 30955 17202
Long Term Investments 1541 2214 3424 2151 1558
Note Receivable - Long Term 965 935 858 893 816
Other Long Term Assets, Total 5887 5977 4475 4326 4716
Total Current Liabilities 22810 23670 22148 24050 22491
Accounts Payable 3866 4535 4357 4144 3645
Accrued Expenses 10587 11186 9753 9111 8535
Notes Payable/Short Term Debt 1639 802 1145 5020 4420
Current Port. of LT Debt/Capital Leases 2313 2799 2580 1898 1373
Other Current Liabilities, Total 4405 4348 4313 3877 4518
Total Liabilities 49548 64048 65844 68287 53706
Total Long Term Debt 17035 20572 23425 23590 20271
Long Term Debt 16194 19760 22538 22580 20227
Capital Lease Obligations 841 812 887 1010 44
Deferred Income Tax 289 3556 3600 3810 1156
Minority Interest -502 6287 6221 6952 -688
Other Liabilities, Total 9916 9963 10450 9885 10476
Total Equity 10598 15055 14587 11405 4360
Common Stock 1347 1347 1346 1346 1345
Additional Paid-In Capital 3440 3301 3281 3174 3091
Retained Earnings (Accumulated Deficit) 6492 10073 8884 6659 -8
ESOP Debt Guarantee -353 -28 -195 -135 -161
Unrealized Gain (Loss) -308 383 1302 409 140
Other Equity, Total -20 -21 -31 -48 -47
Total Liabilities & Shareholders’ Equity 60146 79103 80431 79692 58066
Total Common Shares Outstanding 4034.34 5031.81 4023.99 3962.58 3938.34
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 21240 19348 19719 20769 20249
Cash and Short Term Investments 6683 6504 6975 7877 7161
Cash & Equivalents 3177 3140 2890 3723 3606
Short Term Investments 3506 3364 4085 4154 3555
Total Receivables, Net 8874 7095 7129 7458 8094
Accounts Receivable - Trade, Net 8544 6776 6833 7053 7508
Total Inventory 5480 5512 5355 5146 4659
Other Current Assets, Total 203 237 260 288 335
Total Assets 60862 59461 58596 60146 60313
Property/Plant/Equipment, Total - Net 9454 9315 9414 9620 9650
Goodwill, Net 6973 6716 6857 7046 7195
Intangibles, Net 15295 15531 14160 14318 15589
Long Term Investments 1142 1350 1340 1541 1630
Other Long Term Assets, Total 6758 7201 7106 6852 6000
Total Current Liabilities 22390 22108 20696 22810 20953
Payable/Accrued 15582 13951 14268 16263 16115
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 4843 5921 4261 3952 2793
Other Current Liabilities, Total 1965 2236 2167 2595 2045
Total Liabilities 47729 46770 46776 49548 51161
Total Long Term Debt 15993 15553 16644 17035 19322
Long Term Debt 15993 15553 16644 17035 19322
Deferred Income Tax 402 500 290 289 364
Minority Interest -514 -532 -508 -502 -436
Other Liabilities, Total 9458 9141 9654 9916 10958
Total Equity 13133 12691 11820 10598 9152
Common Stock 1348 1348 1348 1347 1347
Additional Paid-In Capital 3450 3450 3449 3440 3440
Retained Earnings (Accumulated Deficit) 8335 7893 7023 5811 4365
Total Liabilities & Shareholders’ Equity 60862 59461 58596 60146 60313
Total Common Shares Outstanding 4095.03 4095 4094.95 4034.34
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Net income/Starting Line 5096 6388 5268 4046 2169
Cash From Operating Activities 7952 8441 8020 8421 6918
Cash From Operating Activities 1195 1214 1231 954 988
Amortization 1182 1137 1103 902 934
Non-Cash Items 1381 -305 2416 1406 3072
Cash Taxes Paid 1291 1655 1512 1326 1340
Cash Interest Paid 786 864 895 766 781
Changes in Working Capital -902 7 -1998 1113 -245
Cash From Investing Activities -1777 2161 -5354 -1553 -1443
Capital Expenditures -2931 -2239 -2163 -1796 -2202
Other Investing Cash Flow Items, Total 1154 4400 -3191 243 759
Cash From Financing Activities -7589 -10132 -1840 -6389 -6380
Financing Cash Flow Items -1401 -1950 -1453 -10660 -1475
Total Cash Dividends Paid -3999 -3977 -3953 -3927 -3906
Issuance (Retirement) of Stock, Net 21 29 51 74 -9
Issuance (Retirement) of Debt, Net -2210 -4234 3515 8124 -990
Foreign Exchange Effects -29 -39 -82 8 -100
Net Change in Cash -1443 431 744 487 -1005
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Net income/Starting Line 2167 5096 4166 2798 1260
Cash From Operating Activities 2542 7952 4185 1623 331
Cash From Operating Activities 704 2377 2011 1025 361
Non-Cash Items 634 1381 1140 570 433
Cash Taxes Paid 213 1291 857 700 155
Cash Interest Paid 85 786 486 439 95
Changes in Working Capital -963 -902 -3132 -2770 -1723
Cash From Investing Activities -3593 -1777 -1416 -233 -48
Capital Expenditures -601 -2931 -2299 -1015 -354
Other Investing Cash Flow Items, Total -2992 1154 883 782 306
Cash From Financing Activities 7973 -7589 -4815 -3421 -1376
Financing Cash Flow Items 16 -1401 -1052 -883 -391
Total Cash Dividends Paid -952 -3999 -3048 -2097 -946
Issuance (Retirement) of Stock, Net 12 21 20 19 15
Issuance (Retirement) of Debt, Net 8897 -2210 -735 -460 -54
Foreign Exchange Effects 12 -29 -21 -34 -35
Net Change in Cash 6934 -1443 -2067 -2065 -1128

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

GlaxoSmithKline Company profile

About GlaxoSmithKline plc (ADR)

GlaxoSmithKline PLC is a global healthcare company. The Company researches and develops a range of products in three primary areas: Pharmaceuticals, Vaccines and Consumer Healthcare. Its product formulations include tablets, creams/ointments, inhalers, injections, liquids and sterile products. Its Pharmaceuticals business has a portfolio of established medicines in respiratory, human immunodeficiency virus (HIV), immuno-inflammation and oncology. Its Vaccines business has a portfolio of vaccines to help protect people from a range of diseases throughout their lives. Its vaccines tackle diseases, including pneumococcal disease, meningitis, hepatitis, rotavirus, whooping cough and influenza. Its Consumer Healthcare business combines science and consumer insights to create everyday healthcare brands that consumers trust, and experts recommend for oral health, pain relief, cold, flu and allergy, digestive health and vitamins, minerals and supplements.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, GlaxoSmithKline plc (ADR) revenues increased less than 1% to £34.11B. Net income decreased 24% to £4.39B. Revenues reflect Pharmaceuticals segment increase of 4% to £17.73B, US segment increase of 4% to £15.09B, also reflect Consumer Healthcare segment decrease of 4% to £9.61B, Vaccines segment decrease of 3% to £6.78B, Unallocated segment decrease from £28M to £0K.

Equity composition

Ordinary Shs. 25p Par, 05/11, 10B auth., 5,657,488,184 issd., less 494,074,284 Treas. shs. @ Cost. Insiders own 0.02%. PO: NA. 11/91, 9/89, & 2/86,2-for-1 stock splits. 2/00, Company formed through merger with SmithKline Beecham plc @ 1 ADR-for-1.138 ADS of GSK and Glaxo Wellcome plc @ 1.

Industry: Pharmaceuticals (NEC)

980 Great West Road
BRENTFORD
MIDDLESEX TW8 9GS
GB

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

Gold

2,233.43 Price
+1.740% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.80

XRP/USD

0.62 Price
-2.650% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

ETH/USD

3,540.34 Price
-0.930% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

BTC/USD

69,992.70 Price
-1.220% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading